KTX-120, A Novel IRAKIMiD Degrader of IRAK4 and IMiD Substrates, Shows Preferential Activity and Induces Regressions in MYD88-Mutant DLBCL Cell and Patient Derived Xenograft Models
December 7, 2020
62nd American Society of Hematology (ASH) Virtual Annual Meeting and Exposition
Area of Focus
Oncology
Programs
Other
Indications
Other
Development Stage
Pre-clinical Data
Share
